Descripción del proyecto
Cooperación internacional en el fortalecimiento de políticas de medicina personalizada
La medicina personalizada (MP) es un enfoque emergente para la prevención y tratamiento de enfermedades que tiene en cuenta la variabilidad del perfil genético, ambiental y del estilo de vida de cada persona. La MP beneficiará a pacientes, sistemas de salud e industrias de la salud en su conjunto. Los pacientes pueden recibir un mejor tratamiento en términos de eficacia y seguridad mejoradas mediante tratamientos mejor orientados y la intervención en las enfermedades. Los sistemas de salud pueden beneficiarse de mejores diagnósticos y de una asignación más eficiente de los recursos sanitarios al prevenir o retrasar los tratamientos más caros. En el proyecto EULAC-PerMed, financiado con fondos europeos, se creará el Consorcio Internacional de Medicina Personalizada para Latinoamérica y los estados del Caribe, lo que ampliará el alcance de la investigación de la MP y de las políticas relacionadas con la innovación.
Objetivo
In order to strengthen the global efforts on Personalized Medicine (PerMed) and the cooperation of the EU-CELAC countries to them, a unique Bi-regional consortium of governmental and funding organisations is shaped with the support of leading stakeholders as associated partners. This project has the ambition to engage CELAC countries in the International Consortium on Personalized Medicine (ICPerMed) and in the ERANet ERAPerMed with the aim at advancing in the implementation of the Action Plan of ICPerMed based in the Strategic Research and Innovation Agenda, drafted by PerMed2020.
Research on PerMed is a top priority for the EU as a strategy aimed at delivering personalised health and care solutions to benefit citizens. Results of R&I actions will generate and translate knowledge on disease aetiology and technological innovation into personalised health and care solutions. Areas of application include chronic, rare and communicable diseases. Research under this priority will also attempt to develop an outstanding economic impact due to the potential of PerMed to transform health systems.
The collaboration of diverse actors from different world regions, disciplines and health-care systems are needed to implement in a holistic way new feasible and cost-effective PerMed approaches. Involvement in ICPerMed of RFOs and policy-making bodies from EU and from other regions, is the best way to push forward the impact of new findings and knowledge in the area.
This CSA will be the vehicle for: i) Mapping existing programmes, capacities and expertise and gaps in CELAC countries; ii) Facilitating the incorporation of CELAC countries in ICPerMed and in the ERAPerMed; iii) Fostering the participation of CELAC countries in research mobility and transnational projects on PerMed, and a platform for EU‐CELAC collaboration on clinical trials PerMed focused; iv) Cross-border learning from R&I and ELSA for implementing innovations between research capacities based in EU and CELAC.
Ámbito científico
Not validated
Not validated
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SC1-2018-Single-Stage-RTD
Régimen de financiación
CSA - Coordination and support actionCoordinador
28029 Madrid
España